Skip to main content

Setting precedent for disputes involving a challenge against validity of a patent, the Supreme Court concluded that a party opposing grant of patent cannot pursue revocation petitions before the Intellectual Property Appellate Board and simultaneously seek revocation on the same grounds in a counterclaim before the High Court.

 Wind World India Ltd. (WWIL), an erstwhile joint-venture between the appellants (Enercon GmbH) and the respondents, manufactured wind turbines in India under licences granted by the appellants. Pursuant to termination of the licence agreements, WWIL continued to use the patented technologies. WWIL  filed revocation petitions before the Intellectual Property Appellate Board challenging the validity of the patents , and Enercon  filed patent infringement suits before the Delhi High Court. WWIL further filed counter claims under Section 64 of the Patents Act in the lawsuits pending before the High Court .  What resulted was a litigation ‘gridlock’ with two different forums varying in seniority and jurisdictional scope concurrently faced with the same deliberations, i.e. validity of patents.

Deciding appeals before it, the Supreme Court ruled that the same entity cannot approach multiple forums to seek revocation of the same patent. It held thus: when such a situation of parallel proceedings arises, the prior-instituted proceedings for revocation of the patent must survive, unless the patentee and the entity seeking such revocation mutually agree to continue the later-instituted proceedings – in this case the Court held that having pursued their counter-claims for revocation of the appellant’s patents after they had filed revocation proceedings in the IPAB, the respondents had opted for the latter.

The judgment therefore created a framework that balances the patentee’s rights and a person’s right to challenge the validity of a patent.

Dr. Aloys Wobben and another v Yogesh Mehra and others; CA No. 6718/2013 before the Supreme Court of India

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
•
Oct 27, 2026

When a pharmaceutical company develops a new formulation of an existing drug, is it creating a genuine innovation or extending its monopoly over a medicine

Evergreening or Genuine Innovation? The Patentability of New Drug Formulations in India
News & Updates, Thought Leadership
•
Oct 23, 2026

Imagine a researcher using artificial intelligence to identify a new material, a pharmaceutical team using machine learning to discover a promising compound,

Can AI-Assisted Inventions Be Patented in India?
News & Updates, Thought Leadership
•
Oct 20, 2026

Every time someone publishes an article, uploads a photograph, releases a song or shares research online, they contribute to an expanding body of human

Who Owns Internet’s Knowledge? Copyright, AI Training and Indian Law
News & Updates, Thought Leadership
•
Oct 17, 2026

An active pharmaceutical ingredient (API) is the substance responsible for a medicine’s therapeutic effect. Developing one can involve years of chemical

API Process Patents in India: Key Patent Infringement Disputes and Court Decisions